Jenburkt Pharmaceuticals Limited announced its standalone unaudited financial results for the quarter and nine months ended December 31, 2025. The pharmaceutical company's Board of Directors approved the results on February 3, 2026, following recommendations from the Audit Committee.

Financial Performance Overview

The company's financial performance for the third quarter of FY26 showed mixed results compared to the previous year. Revenue from operations declined sequentially but demonstrated year-over-year growth, while profitability faced some pressure during the quarter.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Jenburkt Pharmaceuticals demonstrated solid year-over-year growth across key financial metrics. The company's revenue expansion was supported by improved operational efficiency and market performance.

Expense Analysis

Total expenses for Q3FY26 increased to Rs 3654.22 lacs from Rs 2896.15 lacs in the corresponding quarter of the previous year. The significant expense components included employee benefit expenses of Rs 1471.36 lacs, other expenses of Rs 1209.17 lacs, and purchase of stock-in-trade of Rs 782.71 lacs. The company benefited from a positive change in inventories of Rs 150.93 lacs during the quarter.

Other Comprehensive Income

The company reported total comprehensive income of Rs 652.35 lacs for Q3FY26 compared to Rs 593.16 lacs in Q3FY25. For the nine-month period, total comprehensive income reached Rs 2557.17 lacs against Rs 2550.40 lacs in the previous year.

Corporate Governance

The financial results were reviewed and recommended by the Audit Committee before approval by the Board of Directors. The company noted that it made additional provisions in employee benefit expenses in compliance with the new Labour Codes on Wages 2019. As Jenburkt Pharmaceuticals deals exclusively in the pharmaceuticals business segment, segment-wise reporting is not applicable.

The paid-up equity share capital remained unchanged at Rs 441.33 lacs with a face value of Rs 10 per share. The Board meeting was conducted from 2:30 p.m. to 5:00 p.m. on February 3, 2026.

Source:

Jenburkt Pharmaceuticals Limited has announced its financial results for the second quarter of fiscal year 2026, showcasing robust growth in both revenue and profitability.

Financial Highlights

The company reported a significant increase in its revenue from operations for the quarter ended September 30, 2025. Here's a breakdown of the key financial metrics:

The company's revenue from operations increased by 10.5% year-over-year, reaching Rs 4,555.70 lacs in Q2 FY2026 compared to Rs 4,121.50 lacs in the same quarter last year. This growth demonstrates the company's strong market position and effective business strategies.

Profit after tax also saw a notable rise, increasing by 11.3% to Rs 1,133.20 lacs from Rs 1,018.20 lacs in the corresponding period of the previous fiscal year. This improvement in profitability indicates efficient cost management and operational effectiveness.

Half-Year Performance

For the half-year period ended September 30, 2025, Jenburkt Pharmaceuticals reported total revenue of Rs 8,108.40 lacs, compared to Rs 7,375.16 lacs in the previous year, marking a 10% increase.

Segment Focus

Jenburkt Pharmaceuticals continues to operate exclusively in the pharmaceuticals business segment, maintaining its specialized focus in this industry.

Board Approval and Audit Review

The company's Board of Directors, on the recommendation of the Audit Committee, approved these unaudited financial results in a meeting held on October 28, 2025. The results have undergone a limited audit review by the company's auditors, D.R. Mehta & Associates, who found no material misstatements in the financial reporting.

Conclusion

Jenburkt Pharmaceuticals' Q2 FY2026 results reflect a period of solid growth and improved financial performance. The double-digit increase in both revenue and profit underscores the company's resilience and effective business strategies in the competitive pharmaceutical sector.